The Advanced Research Projects Agency for Health (ARPA-H) has selected five research teams to develop new technologies aimed at making individualized, RNA-based genetic medicines faster and more accessible.
The initiative is part of ARPA-H’s Genetic Medicines and Individualized Manufacturing for Everyone (GIVE) program, which could receive up to 125 million USD in research and development funding. The program seeks to establish an automated, distributed manufacturing network capable of producing genetic medicines on demand and closer to the point of care.
Moving beyond centralized genetic medicine manufacturing
Genetic medicines currently depend heavily on specialized, centralized manufacturing facilities. Production can be slow and expensive, while cold-chain requirements can further complicate transportation and access.
The GIVE program is designed to address these challenges by developing automated manufacturing systems combined with real-time quality control. The long-term goal is to enable individualized RNA-based medicines to be manufactured at multiple locations rather than relying solely on large centralized facilities.
According to ARPA-H, successful development could reduce manufacturing costs and improve access to treatments for patients with cancer, rare genetic disorders and chronic diseases.
Five teams selected for the program
The selected teams will work on automated manufacturing and quality-control technologies:
Centillion Biosciences Inc. will develop an integrated system using cartridge-based DNA/RNA manufacturing, fill-finish, quality-control testing and digital process management.
HDT Bio Corp. will develop an automated platform combining DNA synthesis, chip-based RNA production, closed fill-finish operations and robotics-enabled quality control.
Massachusetts General Hospital will develop a single-use fluidics-based chip and control system designed for continuous manufacturing and quality-control testing. The proposed system could potentially manufacture products in less than three days.
Waterfall Scientific will develop an automated benchtop continuous-flow system integrating DNA production, RNA synthesis, lipid nanoparticle (LNP) formulation and fill-finish operations. Its platform will also incorporate automated quality-control capabilities.
University of Utah will focus on an integrated quality-control platform capable of assessing the identity, purity and potency of genetic medicines. The system is designed to potentially complete full quality control and lot release in as little as one day, using digital microfluidics, advanced optics and artificial intelligence.
FDA to work alongside ARPA-H
The U.S. Food and Drug Administration (FDA) will participate throughout the GIVE program to help develop a regulatory framework for distributed and individualized genetic medicine manufacturing.
ARPA-H said the initiative is intended to establish the technological foundation for manufacturing RNA-based medicines across multiple sites while maintaining appropriate quality and regulatory standards.
Potential impact on personalized medicines
ARPA-H highlighted the example of personalized CRISPR treatment for a child with a rare genetic condition, noting that individualized treatments can currently require months to manufacture and cost hundreds of thousands of dollars.
If the GIVE program succeeds, similar therapies could potentially be produced locally and on demand, reducing manufacturing time and cost. The approach could also help accelerate clinical research and improve access to medicines designed around an individual patient's biology.
The initiative represents a significant shift toward distributed, automated and personalized biomanufacturing, with the potential to change how next-generation genetic medicines are produced and delivered.
